Avalyn Pharma, Inc. (AVLN)
26.04
-1.21
(-4.44%)
USD |
NASDAQ |
Oct 23, 16:00
26.04
0.00 (0.00%)
After-Hours: 20:00
Avalyn Pharma Enterprise Value : 872.76M for Oct. 22, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 22, 2026 | 872.76M |
| October 21, 2026 | 777.89M |
| October 20, 2026 | 756.61M |
| October 19, 2026 | 698.98M |
| October 16, 2026 | 713.61M |
| October 15, 2026 | 757.05M |
| October 14, 2026 | 714.94M |
| October 13, 2026 | 717.15M |
| October 12, 2026 | 764.14M |
| October 09, 2026 | 806.70M |
| October 08, 2026 | 804.93M |
| October 07, 2026 | 796.51M |
| October 06, 2026 | 792.07M |
| October 05, 2026 | 863.01M |
| October 02, 2026 | 911.77M |
| October 01, 2026 | 880.30M |
| September 30, 2026 | 927.73M |
| September 29, 2026 | 866.11M |
| September 28, 2026 | 920.20M |
| September 25, 2026 | 909.56M |
| September 24, 2026 | 930.39M |
| September 23, 2026 | 980.05M |
| September 22, 2026 | 1.103B |
| September 21, 2026 | 1.066B |
| September 18, 2026 | 1.062B |
| Date | Value |
|---|---|
| September 17, 2026 | 1.147B |
| September 16, 2026 | 1.203B |
| September 15, 2026 | 1.184B |
| September 14, 2026 | 1.215B |
| September 11, 2026 | 1.153B |
| September 10, 2026 | 1.202B |
| September 09, 2026 | 1.255B |
| September 08, 2026 | 1.332B |
| September 04, 2026 | 1.322B |
| September 03, 2026 | 1.236B |
| September 02, 2026 | 1.242B |
| September 01, 2026 | 1.229B |
| August 31, 2026 | 1.204B |
| August 28, 2026 | 1.203B |
| August 27, 2026 | 1.283B |
| August 26, 2026 | 1.307B |
| August 25, 2026 | 1.358B |
| August 24, 2026 | 1.336B |
| August 21, 2026 | 1.366B |
| August 20, 2026 | 1.311B |
| August 19, 2026 | 1.392B |
| August 18, 2026 | 1.387B |
| August 17, 2026 | 1.360B |
| August 14, 2026 | 1.405B |
| August 13, 2026 | 1.286B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Filana Therapeutics, Inc. | -51.08M |
| CorMedix, Inc. | 516.90M |
| Eloxx Pharmaceuticals, Inc. | -9.008M |
| Breakthrough Chemistry, Inc. | 0.3383M |
| BioStem Technologies, Inc. | 23.84M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -28.94M |
| Total Expenses (Quarterly) | 28.94M |
| EPS Diluted (Quarterly) | -0.6527 |
| Earnings Yield | -8.10% |
| Normalized Earnings Yield | -8.099 |